Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes

(2022) Aleksandr Zaitsev et al.   CANCER CELL

The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma

(2021) Eileen M. Boyle et al.   Nature Communications

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

(2021) Nikhil C. Munshi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures

(2021) Nikita Kotlov et al.   Cancer Discovery

Facts and Hopes in Multiple Myeloma Immunotherapy

(2021) Adam S. Sperling et al.   CLINICAL CANCER RESEARCH

RAF-MEK-ERK pathway in cancer evolution and treatment

(2021) Rahim Ullah et al.   SEMINARS IN CANCER BIOLOGY

IgM-MM is predominantly a pre–germinal center disorder and has a distinct genomic and transcriptomic signature from WM

(2021) Abdul Hamid Bazarbachi et al.   BLOOD

FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology

(2021) Cirino Botta et al.   Blood Advances

Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma

(2020) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression

(2020) Mark Bustoros et al.   JOURNAL OF CLINICAL ONCOLOGY

Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice

(2020) Zhi Wen et al.   BLOOD

Cancer immunoediting and immune dysregulation in multiple myeloma

(2020) Kyohei Nakamura et al.   BLOOD

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard and high risk myeloma

(2020) Ibai Goicoechea et al.   BLOOD

The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies

(2020) Shogo Kumagai et al.   NATURE IMMUNOLOGY

Endogenous retroelement activation by epigenetic therapy reverses the Warburg effect and elicits mitochondrial-mediated cancer cell death

(2020) Vicente Fresquet et al.   Cancer Discovery

Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy

(2019) Marie-Eve Beaulieu et al.   Science Translational Medicine

Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient

(2019) Irene Ghobrial et al.   Clinical Lymphoma Myeloma & Leukemia

Monoclonal gammopathy of undetermined significance (MGUS)

(2019) Tarek H Mouhieddine et al.   BLOOD

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

(2019) Maria-Victoria Mateos et al.   Lancet Haematology

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

(2019) Saad Zafar Usmani et al.   Lancet Haematology

MYC dysregulation in the progression of multiple myeloma

(2019) Kristine Misund et al.   LEUKEMIA

Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy

(2019) Huiying Han et al.   CANCER CELL

Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma

(2019) Sagar Lonial et al.   JOURNAL OF CLINICAL ONCOLOGY

Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment

(2018) Kyohei Nakamura et al.   CANCER CELL

Blocking IFNAR1 inhibits multiple myeloma–driven Treg expansion and immunosuppression

(2018) Yawara Kawano et al.   JOURNAL OF CLINICAL INVESTIGATION

The multiple myelomas — current concepts in cytogenetic classification and therapy

(2018) Shaji K. Kumar et al.   Nature Reviews Clinical Oncology

CrbnI391Vis sufficient to conferin vivosensitivity to thalidomide and its derivatives in mice

(2018) Emma C. Fink et al.   BLOOD

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

(2018) T A Chan et al.   ANNALS OF ONCOLOGY

A novel allele for inducible Cre expression in germinal center B cells

(2018) Timm Weber et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Antigen receptor repertoire profiling from RNA-seq data

(2017) Dmitriy A Bolotin et al.   NATURE BIOTECHNOLOGY

Multiple myeloma

(2017) Shaji K. Kumar et al.   Nature Reviews Disease Primers

MGUS to myeloma: a mysterious gammopathy of underexplored significance

(2016) M. V. Dhodapkar   BLOOD

BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice

(2016) Mohamed-Amine Hamouda et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice

(2016) Rituparna Das et al.   NATURE MEDICINE

Genomic complexity of multiple myeloma and its clinical implications

(2016) Salomon Manier et al.   Nature Reviews Clinical Oncology

MYC regulates the antitumor immune response through CD47 and PD-L1

(2016) S. C. Casey et al.   SCIENCE

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS

(2015) Jan Krönke et al.   NATURE

Massively Parallel Single-Cell RNA-Seq for Marker-Free Decomposition of Tissues into Cell Types

(2014) D. A. Jaitin et al.   SCIENCE

Mantle cell lymphoma in cyclin D1 transgenic mice with Bim-deficient B cells

(2013) S. G. Katz et al.   BLOOD

Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells

(2013) B. A. Walker et al.   BLOOD

Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma

(2013) María-Victoria Mateos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Synergy between PI3K Signaling and MYC in Burkitt Lymphomagenesis

(2012) Sandrine Sander et al.   CANCER CELL

NIH Image to ImageJ: 25 years of image analysis

(2012) Caroline A Schneider et al.   NATURE METHODS

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Novel Transgenic Mouse Model of the Human Multiple Myeloma Chromosomal Translocation t(14;16)(q32;q23)

(2011) Naoki Morito et al.   CANCER RESEARCH

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

Constitutive Canonical NF-κB Activation Cooperates with Disruption of BLIMP1 in the Pathogenesis of Activated B Cell-like Diffuse Large Cell Lymphoma

(2010) Dinis Pedro Calado et al.   CANCER CELL

Multiple layers of B cell memory with different effector functions

(2009) Ismail Dogan et al.   NATURE IMMUNOLOGY

AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies

(2008) Marta Chesi et al.   CANCER CELL

Therapeutic Antitumor Efficacy of Anti-CD137 Agonistic Monoclonal Antibody in Mouse Models of Myeloma

(2008) O. Murillo et al.   CLINICAL CANCER RESEARCH